Tagged with Shire

Greece A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and haemophilia drugs from clawbacks to circumvent market challenges for critical treatments, as well as his vision for the bright future…

Mexico Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Shire France’s General Manager, Andrew Obenshain, speaks optimistically about the leading market conditions in France, the corporate culture of a multinational company in a niche market, and building a rapport with government and patients. As an American working in France, what are your key observations about the differences and similarities…

Nordics Mary Di Marzio has been General Manager of Nordics for Shire Inc for nearly 2 years now. Today she shares with Pharmaboardroom the progress of Shire’s relatively new branch in Scandinavia. She continues to give insights into the balancing act between pricing versus reimbursement and how they are raising awareness…

Shire Brazil Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry here in Brazil? First of all, the government must keep the status quo to respect intellectual property. This is imperative,…

Shire Brazil We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there a different approach required in the specific area of HGT? For HGT, one very important element is the basic regulatory…

Shire Pharmaceuticals Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way? Shire started operations in Mexico in 2008, a similar story to Brazil. There are very few people working here in Shire Mexico but we…

Shire International Licensing BV Netherlands Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these four continents. What is the strategic role that Shire Netherlands plays and how does this role fit into the group’s…

Shire Deutschland The acquisition of Jerini has to be one of the biggest milestones for Shire Deutschland in its recent history. How have the synergies developed between the two companies, and how is the integration progressing? To quote Dr Werner Föller, head of Shire Deutschland’s Human Genetic Therapies Business Unit, “The integration…